Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Er...very serious buy / add opportunity down here. Nom nom...
100% agree. Khiron has a golden set-up and I wholeheartedly believe it is the best cannabis investment at this point.
Noted re Zinc for sore throats...many thanks, Mike!
Great add / buy price right here.
MindMed has developed the ability to remove the (often uncomfortable) "trip" from the dosage but maintain the benefits. Massively pioneering.
I have, do and will continue to do so. What you put in your body is your business obviously but do not assume we all follow suit. Truthfully, your overall claim ref India being such a concern / negative in the context of our shared investment is so inflated. Btw I am not Indian and I live in the U.S. Good luck to us all. My sense is we are being positioned for success here. Adding to my already sizable share count regularly and holding.
I agree. Good ole Crypto.com also.
Me too. Big confidence in ATAI.
This company and stock is going to fly given time IMO. As such, I am taking full advantage by buying (adding) often.
Serious Buy time IMO. Good luck whatever direction your junk hangs peeps.
Not worried. Today was a shock announcement-driven crash thanks to SBF and Binance. DOGE shall prevail soon enough IMO.
100% agree reSolana’s future. Examine the utility, people. Easy investment.
Covid is most certainly not over. We need to tactfully and tastefully spread the word about Bucillamine and it’s diverse health benefits. The saddest most cruel outcome would be for it to be passed by (for whatever flawed 2020’s / Big Pharma reason). #ittakesonebigpharmatorulecovidsolutuonsjesush
Bag holding frankly. Leadership are yet to produce any shareholder value. Hope this is not a scam per se.
Exactly. Buying more SHIB regularly for the future.
Down almost -6% based on a mere x15 shares traded so far this morning. This stinks of manipulation. Revolting.
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
Post published:November 2, 2022
Post category:Press Release
TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, is pleased to announce that the Company has entered into an evaluation and exclusive option agreement (the “Agreement”) with Case Western Reserve University (“CWRU”) in the development and commercialization for the intellectual property of ketamine in the treatment Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial (NCT03633058) for Rett syndrome and unpublished results will be evaluated to support a defined clinical and regulatory plan for FDA feedback.
“We are pleased to have added the Rett syndrome program to our clinical stage product pipeline that focuses on novel uses and delivery forms of ketamine in the treatment of mental health, neurological and pain disorders,” said Fabio Chianelli, CEO of PharmaTher. “In research, ketamine has shown the potential for treating Rett syndrome. We will work with CWRU and the clinical trial team in pursuing discussions with the FDA to determine all regulatory and clinical options that could expedite the pathway towards having ketamine available for Rett syndrome patients.”
Currently, there is no known cure or FDA-approved drugs for treating Rett syndrome. According to the Rett Syndrome Foundation, Rett syndrome is a rare genetic neurological disorder that occurs almost exclusively in girls. It leads to severe impairments in their ability to speak, walk, eat, and even breathe easily. Prominent features of Rett syndrome include near constant repetitive hand movements and loss of purposeful hand use. Rett syndrome is usually recognized in children between 6 to 18 months. Rett syndrome is caused by mutations on the X chromosome on a gene called MECP2. Rett syndrome occurs worldwide in 1 of every 10,000 female births, and is much rarer in boys.
Ketamine has the potential to treat Rett syndrome, which has been independently validated in two different laboratories in two different strains of Mecp2 mice and has completed a Phase 2 clinical trial with Rett syndrome, with results not published. The therapeutic potential of ketamine for treating Rett syndrome was first demonstrated by Dr. David M. Katz, Professor Emeritus, Department of Neurosciences, School of Medicine at CWRU, and colleagues, who found that treatment of heterozygous female Mecp2 mutant mice with a subanesthetic dose of ketamine (8 mg/kg) acutely reversed abnormalities in Fos expression and sensorimotor function [1]. Chronic administration of ketamine was also found to improve symptoms and extend lifespan in null male Mecp2 mutants [2]. The ability of low-dose ketamine to improve function across a broad range of symptoms may be related to its ability to increase cortical network activity, possibly by selective inhibition of GABAergic interneurons [3], as well as to decrease synaptic excitability in brainstem networks important for respiratory and autonomic control [4]. Thus, ketamine may be ideally suited to redress the imbalance between cortical and brainstem activity that characterizes the MeCP2-deficient brain. Moreover, in addition to its acute effects on circuit function, work in other disease models has shown that ketamine also rapidly stimulates dendritic growth, BDNF levels, and expression of key synaptic proteins [5, 6], at least in part through activation of mTOR signaling, which is deficient in Mecp2 mutants [7]. These findings suggest that, in addition to acute rescue of neurological function, ketamine also has the potential to promote synaptic repair in Rett syndrome by enhancing structural and functional connectivity, as previously shown in animal models of depression and stress [8].
Under the terms of the Agreement, PharmaTher gained an exclusive option for up to 12 months to evaluate the regulatory, clinical development and commercialization plan for CWRU’s intellectual property portfolio, which includes, US issued patent no. 11,213,494 and US provisional patent no. 62/312,749 entitled, “Composition and method for the treatment of pervasive development disorders”, and US provisional patent no. 62/004,695 entitled, “Acute and sustained effects of low-dose ketamine treatment in mouse models of Rett Syndrome.” Consistent with industry standards, PharmaTher paid a one-time fee for entering into the Agreement, and should the Company elect to exercise its option, both the Company and CWRU will negotiate a license agreement.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders. PharmaTher’s product portfolio consists of KETARX™ (ketamine) delivered by intravenous injection, intradermal microneedle patch, and subcutaneous pump administration. Learn more at PharmaTher.com.
For more information about PharmaTher, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
Hadn’t forgotten but this deal just won’t suffice. More deals needed. Way more.
The tech appears very innovative however, the CEO Bunka should be replaced in my opinion. Pays himself an inflated package but is yet to significantly monetize the business to merit or justify it.
New, more capable CEO preferred to sign deals and create shareholder value.
Bag holders mostly at this point we “Long” investors are.
Excellent. As anticipated. Huge future for SHIB too IMO.
Bought a billion. Well worth the bet IMO.
Excellent. As anticipated. Huge future for DOGE.
Agreed. I love their science, mission and potential but I now hate the CEO as he is very weak in the area of investor sentiment / relations for starters. As a CEO you can get away with that on the OTCM however, MindMed is trading on the NASDAQ yet he is pure shite IMO.
Immense buy-in opportunity for new newbies + add time for us Longs right here IMO.
Buy time. Simple as. Unless you are a thick *unt that is.
Buying all can.
Bargain Basement share price here. Just incredible given the pending FDA decision (plus Bucillamine’s health & healing benefits).
Puke. You absolute Wrong’un
100% agree that the right masks work. Our little boy finally got Covid this summer however, neither my wife nor I developed symptoms / tested positive because we all wore masks at home for those 8+ days. This is just one example of proof that decent N95 type masks are worth wearing.
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology:
Post published:October 19, 2022
Post category:Press Release
– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal INB-01, a sol-gel based drug-delivery technology.
– INB-01 may enable direct-to-brain delivery of various compounds in development across atai’s pipeline, with topline results expected in H1 2023.
– Potential advantages may include ease of administration, increased patient compliance, lower dose requirements, rapid onset of action, and minimized systemic exposure.
NEW YORK and BERLIN, Oct. 18, 2022 (GLOBE NEWSWIRE) — atai Life Sciences (“atai” or the “Company”) (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders today announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug-delivery) technology.
This is a Phase 1 two-stage, open-label, randomized study of the safety, tolerability, and effective brain delivery of INB-01. INB-01 or placebo will be administered to subjects using the Aptar Nasal Drug Delivery Device. Topline results are expected in H1 2023.
Traditional oral or intravenous drug delivery methods can be problematic in the treatment of central nervous system (CNS) disorders. When drugs are delivered via these peripheral methods, the blood–brain barrier restricts the entry of therapeutic agents to the CNS, thereby decreasing drug efficacy.
A potential solution is direct-to-brain delivery through the nose. This method has the potential to be a non-invasive administration route and may offer additional advantages such as ease of administration, increased patient compliance, lower dose requirements, rapid onset of action, and minimized systemic exposure, which may reduce the risk of peripheral toxicity.
Our INB-01 technology is designed to deliver pharmaceutical compounds as a liquid at room temperature, which becomes a gel instantaneously in the nasal cavity. The novel technology has been successfully utilized with both water-soluble and insoluble compounds and extracts. Prior to launching this PoC trial in humans, dosing of INB-01 has shown positive results in animals when measuring levels of INB-01 in the brain as well as MRI imaging of the brain. These results are a promising predictor for the use of INB-01 in human subjects for intranasal direct-to-brain drug delivery.
“Exploring the mechanism of drug delivery is an opportunity for us to further enhance the treatment experience,” said Florian Brand, Co-Founder, and CEO of atai Life Sciences. “INB-01 has the potential to provide superior drug uptake via the nose-brain barrier, reducing dose administered and dosing frequency. We are confident this will help patients and healthcare practitioners by easing administration, dosing, and providing faster relief to improve compliance.”
Dr. Majed Fawaz, Vice President, Chemistry, Manufacturing & Controls at atai, further commented, “INB-01 offers a novel direct-to-brain delivery technology that will support the lifecycle of atai’s drug development pipeline. We are thrilled to commence the Phase 1 proof-of-concept trial for INB-01. This is the first important step in understanding the safety, tolerability, and brain delivery potential of INB-01 in healthy adult subjects prior to pairing it with active pharmaceutical ingredients.”
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.
atai’s vision is to heal mental health disorders so that everyone, everywhere, can live a more fulfilled life. For more information, please visit www.atai.life
Interesting day so far with high volume.
You traded ILUS on the wrong day and lost your lunch money just admit it.
I am certainly buying this dip as it is way too soon for the FDA to have concluded their response to the trial data submitted only this week.
LOL nope you bell end.
MM manipulation in play or daft twats risking flipping even today. Talk about the 59th minute of the 11th hour type stuff..
In Vegas and it's only 09:14am however, I am already thinking about starting drinking! It is now after 5pm in England after all.
Had to buy big down here.
I agree we should expect an update before this weekend. Might not be conclusive news from the FDA but we ought to hear from Michael Frank in some form.
I was fine giving him/her/it 45 seconds of my time if it leads to him/her/it having a positive word with itself.
Long term play indeed. I love the science and the potential however, I despise MindMed's CEO Robert Barrow plus his I.R. dept for the ATTROCIOUS JOB they are doing with respect to addressing the recent PPS action with the shareholders. Piss poor to say the least. Implore them to correct this and create shareholder value moving forward.
Loading time for me down here fellas. Far too much ahead for SHIB to not in my opinion.
IMO DOGE will do great in time. Just need to stick with it and load up big time..particularly down here.